We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$35.9M
Cap. Flow %
-2.87%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Consumer Discretionary 0.07%
3 Financials 0.04%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
51
Aldeyra Therapeutics
ALDX
$97.1M
$5.58M 0.45%
957,193
+87,393
+10% +$683K
RLYP
52
CALL
DELISTED
RELYPSA INC COM
RLYP
$5.55M 0.44%
+300,000
New +$8.24M
ARDX icon
53
Ardelyx
ARDX
$1.24B
$5.46M 0.44%
315,955
– –
THOR
54
DELISTED
THORATEC CORPORATION
THOR
$5.44M 0.43%
86,000
-140,000
-62% -$8.32M
AFMD
55
DELISTED
Affimed
AFMD
$5.36M 0.43%
86,862
-15,520
-15% -$1.92M
SIOX
56
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.3M 0.42%
51,250
+27,500
+116% +$3.22M
ANTH
57
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.21M 0.42%
124,020
-26,250
-17% -$1.83M
ELDN icon
58
Eledon Pharmaceuticals
ELDN
$255M
$5.02M 0.4%
2,996
– –
RLYP
59
PUT
DELISTED
RELYPSA INC COM
RLYP
$4.63M 0.37%
+250,000
New +$6.87M
FPRX
60
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.37M 0.35%
284,129
+60,000
+27% +$1.29M
NERV icon
61
Minerva Neurosciences
NERV
$191M
$4.25M 0.34%
101,317
– –
ASXC
62
DELISTED
Asensus Surgical, Inc.
ASXC
$4.13M 0.33%
140,495
-16,738
-11% -$621K
TARA icon
63
Protara Therapeutics
TARA
$214M
$3.83M 0.31%
6,875
– –
HEWG
64
DELISTED
iShares Currency Hedged MSCI Germany ETF
HEWG
$3.29M 0.26%
145,000
+58,000
+67% +$1.45M
STJ
65
DELISTED
St Jude Medical
STJ
$3.25M 0.26%
+51,520
New +$3.68M
CYAD
66
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$3.14M 0.25%
75,000
– –
WBA
67
DELISTED
Walgreens Boots Alliance
WBA
$2.93M 0.23%
35,292
– –
RGEN icon
68
PUT
Repligen
RGEN
$6.91B
$2.79M 0.22%
+100,000
New +$3.61M
PTCT icon
69
CALL
PTC Therapeutics
PTCT
$6.18B
$2.67M 0.21%
+100,000
New +$4.28M
CI icon
70
Cigna
CI
$78.4B
$2.63M 0.21%
19,470
-2,500
-11% -$363K
ARIA
71
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.63M 0.21%
450,000
+258,051
+134% +$1.99M
CPRX
72
DELISTED
Catalyst Pharmaceutical
CPRX
$2.55M 0.2%
851,200
– –
AKBA icon
73
Akebia Therapeutics
AKBA
$338M
$2.51M 0.2%
+260,000
New +$2.39M
MGCD
74
DELISTED
MGC Diagnostics Corporation
MGCD
$2.22M 0.18%
336,287
– –
VTAE
75
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.2M 0.18%
200,000
+50,000
+33% +$531K
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q3 2015 filing shows 40 new, 31 increased, 43 reduced and 54 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M. The largest sale was ZS PHARMA INC COMS TK (DE), an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.